SCHEMBL7252894

SCHEMBL7252894

CC(O)n1ncc2ccc(-c3ccsc3)cc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR1D P28221 1/20 0.41
▸ HTR7 P34969 1/20 0.40
▸ BACE1 P56817 1/20 0.40
▸ DRD2 P14416 1/20 0.39
▸ HTR6 P50406 1/20 0.39
▸ EEF2K O00418 1/20 0.38
▸ DYRK3 O43781 1/20 0.38
▸ JAK2 O60674 1/20 0.38
▸ RPS6KA5 O75582 1/20 0.38
▸ PRKD3 O94806 1/20 0.38
▸ MAP4K4 O95819 1/20 0.38
▸ CDK1 P06493 1/20 0.38
▸ PIM1 P11309 1/20 0.38
▸ CLK2 P49760 1/20 0.38
▸ CDK5 Q00535 1/20 0.38
▸ CAMK2B Q13554 1/20 0.38
▸ CAMK2G Q13555 1/20 0.38
▸ CAMK2D Q13557 1/20 0.38
▸ DYRK1A Q13627 1/20 0.38
▸ PKN2 Q16513 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6615897 0.77 PDGFRB (0.37) PDGFRBPDGFRA
SCHEMBL7256498 0.73 EEF2K (0.46) HTR1DHTR7BACE1EEF2KDYRK3
SCHEMBL7253584 0.73 HTR1D (0.42) HTR1DHTR7BACE1DRD2HTR6
SCHEMBL7253036 0.72 KMO (0.46) HTR1DHTR7CDK5DYRK1AKMO
SCHEMBL30833792 0.72 CHEK1 (0.43) HTR1DHTR7PIM3CLK4KMO
SCHEMBL7253520 0.70 HTR1D (0.44) HTR1DHTR7BACE1EEF2KDYRK3
SCHEMBL7253008 0.70 HTR1D (0.62) HTR1DHTR7BACE1EEF2KDYRK3
SCHEMBL7256527 0.69 HTR1D (0.43) HTR1DHTR7BACE1EEF2KDYRK3
SCHEMBL7258088 0.69 HTR1D (0.57) HTR1DHTR7BACE1MAP4K4KMO
SCHEMBL7253398 0.69 HTR1D (0.48) HTR1DHTR7BACE1DRD2HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6635639-B2 Treatment or diagnosis of central nervous system conditions NPS ALLELIX CORP. (CA) 2003-10-21 — — US disclosed
US-20020169322-A1 Use of N-alkylamino-heterocylic compounds for the treatment of migraine NPS ALLEXLIX CORP. 2002-11-14 — — US disclosed
US-6380242-B1 FOR DIAGNOSIS AND THERAPY OF CENTRAL NERVOUS SYSTEM CONDITIONS NPS ALLELIX CORP. (CA) 2002-04-30 — — US disclosed
EP-1140074-A1 INDOLE AND INDOLIZIDINE DERIVATIVES FOR THE TREATMENT OF MIGRAINE NPS Allelix Corp. (CA) 2001-10-10 — — EP disclosed
WO-2000038677-A1 INDOLE AND INDOLIZIDINE DERIVATIVES FOR THE TREATMENT OF MIGRAINE ALLELIX BIOPHARMACEUTICALS INC. (CA) 2000-07-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020169322-A1 Use of N-alkylamino-heterocylic compounds for the treatment of migraine CNR1, CNR2, KCNH1 HTR1D 128/4885HTR7 73/4885BACE1 1294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback